Krystal Biotech, Inc.

KRYS - CIK 0001711279

Market cap$9.21 B

Rank#989

SEC filings483

Krystal Biotech, Inc. trades as KRYS and has a market capitalization of $9.21 B, making it the #989 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $389.13M, up 33.9% from the prior year and net income of $204.83M. This page tracks Krystal Biotech, Inc. through 483 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$389.13MFY 2025

Net income (latest FY)$204.83MFY 2025

Operating cash flow (latest FY)$200.87MFY 2025

Total assets (latest FY)$1.33BFY 2025

Net margin52.6%latest FY

Financial performance

Net profit margin expanded from 21.6% to 52.6% over the same period - every figure below comes from the company's audited annual filings.

KRYS annual revenueView details

KRYS annual net incomeView details

Key statistics

Market cap: $9.21 B
Share price (derived)market cap / shares outstanding: $312.41
P/E ratio (trailing FY): 45.0
EPS (diluted)FY 2025: $6.84
Shares outstandingas of 2026-04-29: 0.03B
Total equityas of 2026-03-31: $1.28B
Return on equity: 16.0%
Cash & equivalentsas of 2026-03-31: $501.31M

Latest filings

Filing	Type	Filed
Insider sale notice	144	2026-05-26
Major company event	8-K	2026-05-20
Major company event	8-K	2026-05-04
Quarterly report	10-Q	2026-05-04
SCHEDULE 13G/A	-	2026-05-04
SCHEDULE 13G	-	2026-04-29
Annual report to shareholders	ARS	2026-04-03
Proxy materials	DEFA14A	2026-04-03

Browse the full filing history (483 filings)

Recent press releases

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa2026-05-18
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa | Krystal Biotech, Inc.
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference2026-05-07
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference | Krystal Biotech, Inc.
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results2026-05-04
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results | Krystal Biotech, Inc.
Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 20262026-05-04
Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53916 .
Krystal Biotech to Present at Upcoming Scientific Conferences2026-04-30
Krystal Biotech to Present at Upcoming Scientific Conferences | Krystal Biotech, Inc.

Similar companies

The largest companies sharing Krystal Biotech, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).

AMGNAmgen Inc.$183.41 B KRYS vs AMGN

GILDGilead Sciences, Inc.$151.05 B KRYS vs GILD

ARGXargenx SE$53.35 B KRYS vs ARGX

RVMDRevolution Medicines, Inc.$30.65 B KRYS vs RVMD

BIIBBiogen Inc.$28.68 B KRYS vs BIIB

Frequently asked questions

What is Krystal Biotech, Inc.'s market cap?

Krystal Biotech, Inc. (KRYS) has a market capitalization of $9.21 B as of 2026-06-10, ranking #989 among US-listed companies.

How much revenue does Krystal Biotech, Inc. make?

Krystal Biotech, Inc. reported revenue of $389.13M for fiscal year 2025, an increase of 33.9% year over year.

Is Krystal Biotech, Inc. profitable?

Yes. Krystal Biotech, Inc. reported net income of $204.83M in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.